Jørn Herrstedt

Jørn Herrstedt

    Member of:

    • Clinical Oncology


    Publication year:
    All
    1 - 10 out of 53Page size: 10
    1. 2024
    2. Published

      2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting

      Herrstedt, J., Clark-Snow, R., Ruhlmann, C. H., Molassiotis, A., Olver, I., Rapoport, B. L., Aapro, M., Dennis, K., Hesketh, P. J., Navari, R. M., Schwartzberg, L., Affronti, M. L., Garcia-Del-Barrio, M. A., Chan, A., Celio, L., Chow, R., Fleury, M., Gralla, R. J., Giusti, R., Jahn, F. & 14 others, Iihara, H., Maranzano, E., Radhakrishnan, V., Saito, M., Sayegh, P., Bosnjak, S., Zhang, L., Lee, J., Ostwal, V., Smit, T., Zilic, A., Jordan, K., Scotté, F. & participants of the MASCC/ESMO Consensus Conference 2022, P. O. T. M. C. C. 2., 2024, In: ESMO Open. 9, 2, 18 p., 102195.

      Research output: Contribution to journal › Journal article › Research › peer-review

    3. Published

      Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer

      Meteran, H., Knudsen, A. &., Jørgensen, T. L., Nielsen, D. & Herrstedt, Jørn, 2024, In: Journal of Clinical Medicine. 13, 3, 12 p., 897.

      Research output: Contribution to journal › Journal article › Research › peer-review

    4. Published

      Impact of FRAilty screening and Geriatric assessment and INtervention in older patients with epithelial Ovarian Cancer: A multicenter randomized clinical trial protocol (FRAGINOC)

      Daviu Cobián, C., Oreskov, J. O., Blaakaer, J., Jespersen, E., Jørgensen, T. L., Ryg, J., Herrstedt, Jørn, Høgdall, Claus Kim, Lund, Cecilia Margareta, Seibæk, L., Vinther, A., Ekmann-Gade, A. W. & Schnack, T. H., 2024, In: Journal of Geriatric Oncology. 15, 3, 12 p., 101713.

      Research output: Contribution to journal › Journal article › Research › peer-review

    5. 2023
    6. Published

      2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents

      Herrstedt, Jørn, Celio, L., Hesketh, P., Zhang, L., Navari, R., Chan, A., Saito, M., Chow, R. & Aapro, M., 2023, In: Supportive Care in Cancer. 32, 1, 12 p., 47.

      Research output: Contribution to journal › Journal article › Research › peer-review

    7. Published

      Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles

      Navari, R., Binder, G., Molasiotis, A., Herrstedt, Jørn, Roeland, E. J., Ruddy, K. J., LeBlanc, T. W., Kloth, D. D., Klute, K. A., Papademetriou, E., Schmerold, L. & Schwartzberg, L., 2023, In: The Oncologist. 28, 3, p. 208-213 6 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    8. Published

      MASCC/ESMO antiemetic guidelines: Introduction to the 2023 guidelines update

      Herrstedt, Jørn, Clark-Snow, R., Ruhlmann, C. H., Jordan, K. & Scotté, F., 2023, In: Supportive Care in Cancer. 32, 1, 4 p., 57.

      Research output: Contribution to journal › Editorial › Research › peer-review

    9. Published

      Prevalence and predictors of long-delayed (> 120 h) chemotherapy-induced nausea and vomiting (CINV) — a systematic review and individual patient data meta-analysis

      Chow, R., Yin, L. B., Baqri, W., Huang, R., Boldt, G., Younus, J., Lock, M., Prsic, E., Zimmermann, C. & Herrstedt, Jørn, 2023, In: Supportive Care in Cancer. 31, 8, 11 p., 505.

      Research output: Contribution to journal › Review › Research › peer-review

    10. Published

      Prevention of taste alterations in patients with cancer receiving Paclitaxel- or Oxaliplatin-based chemotherapy — A pilot trial of cannabidiol

      Dominiak, H. S. H., Hasselsteen, S. D., Nielsen, S. W., Andersen, Jens Rikardt & Herrstedt, Jørn, 2023, In: Nutrients. 15, 13, 10 p., 3014.

      Research output: Contribution to journal › Journal article › Research › peer-review

    11. 2022
    12. Published

      Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects

      Mirza, M. R., Lindahl, G., Mahner, S., Redondo, A., Fabbro, M., Rimel, B. J., Herrstedt, Jørn, Oza, A. M., Canzler, U., Berek, J. S., González-Martín, A., Follana, P., Lord, R., Azodi, M., Estenson, K., Wang, Z., Li, Y., Gupta, D., Matulonis, U. & Feng, B., 2022, In: Cancer research communications. 2, 11, p. 1436-1444 9 p.

      Research output: Contribution to journal › Journal article › Research › peer-review

    13. Published

      Addressing Chemotherapy-Induced Peripheral Neuropathy Using Multi-Frequency Vibrometry and Patient-Reported Outcomes

      Nielsen, S. W., Lindberg, S., Ruhlmann, C. H. B., Eckhoff, L. & Herrstedt, Jørn, 2022, In: Journal of Clinical Medicine. 11, 7, 12 p., 1862.

      Research output: Contribution to journal › Journal article › Research › peer-review

    Previous 1 2 3 4 5 6 Next

    ID: 182566628